Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

2.

Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.

Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR.

Neuropsychopharmacology. 2005 Nov;30(11):2046-57.

4.
5.

Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.

Lichtman AH, Sheikh SM, Loh HH, Martin BR.

J Pharmacol Exp Ther. 2001 Sep;298(3):1007-14.

6.
8.

Cannabinoid effects on behaviors maintained by ethanol or food: a within-subjects comparison.

Ginsburg BC, Lamb RJ.

Behav Pharmacol. 2006 May;17(3):249-57.

PMID:
16572003
9.

Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway.

Caillé S, Parsons LH.

Neuropsychopharmacology. 2006 Apr;31(4):804-13.

10.

Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.

Marusich JA, Wiley JL.

Pharmacol Biochem Behav. 2012 Jun;101(4):575-80. doi: 10.1016/j.pbb.2012.03.004.

11.

Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats.

Sink KS, Segovia KN, Nunes EJ, Collins LE, Vemuri VK, Thakur G, Makriyannis A, Salamone JD.

Psychopharmacology (Berl). 2009 Oct;206(2):223-32. doi: 10.1007/s00213-009-1602-8.

12.

The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.

Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK, Peng Y, Olszewska T, Thakur GA, Makriyannis A, Parker LA, Salamone JD.

Neuropsychopharmacology. 2008 Mar;33(4):946-55. Erratum in: Neuropsychopharmacology. 2008 Jun;33(7):1776. Pang, Yan [corrected to Peng, Yan]; Olzewska, Teresa [corrected to Olszewska, Teresa].

13.

Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.

Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A, Goldberg SR, Le Foll B.

Addict Biol. 2012 Jan;17(1):47-61. doi: 10.1111/j.1369-1600.2011.00314.x.

PMID:
21521420
14.

The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice.

Shafaroodi H, Samini M, Moezi L, Homayoun H, Sadeghipour H, Tavakoli S, Hajrasouliha AR, Dehpour AR.

Neuropharmacology. 2004 Sep;47(3):390-400.

PMID:
15275828
15.

Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.

Fattore L, Spano M, Melis V, Fadda P, Fratta W.

Br J Pharmacol. 2011 Aug;163(7):1550-62. doi: 10.1111/j.1476-5381.2011.01459.x.

16.

Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.

Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH.

J Pharmacol Exp Ther. 1998 Aug;286(2):697-703.

18.

Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors.

Takahashi RN, Ramos GA, Assini FL.

Pharmacol Biochem Behav. 2003 Jul;75(4):763-8.

PMID:
12957217
19.

Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.

Maccioni P, Pes D, Carai MA, Gessa GL, Colombo G.

Behav Pharmacol. 2008 May;19(3):197-209. doi: 10.1097/FBP.0b013e3282fe8888.

PMID:
18469537
20.

Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Viganò D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, Parolaro D.

Psychopharmacology (Berl). 2005 Nov;182(4):527-36.

PMID:
16079992

Supplemental Content

Support Center